Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

Pune: The untimely death of a 25-year-old BHMS student in a Jalna two-wheeler accident on Dec 29, 2025, broke his family's ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...

Serum CXCL6 was higher in ANCA-associated vasculitis with interstitial lung disease and independently predicted ILD progression, suggesting a blood biomarker to identify AAV-ILD and monitor risk.

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Credit: Getty Images The ATS/ERS 2025 statement on interstitial pneumonia classification, an update of the 2013 statement, reflects new thinking on IP, PPF, molecular pathology, and treatments. The ...

A chronic lung disease is a type of disease that prevents the lungs and respiratory system from working correctly. The main job of the respiratory system is to take in oxygen from the air we breathe ...

Individuals with interstitial lung disease (ILD) had more than a 13-fold higher incidence rate of lung cancer than those without ILD. The association persisted after adjustment for confounders, was ...